pharmaphorum

SEPTEMBER 15, 2022

Aldeyra Therapeutics’ dogged persistence with its drug eye disease therapy reproxalap – despite mixed results in a phase 3 trial – may be paying off. The post Aldeyra spies FDA filing ahead for dry eye drug reproxalap appeared first on. Sales were nevertheless solid at $468 million and $1.29

FDA 52

FDA Side effects Prospecting Patients 52

pharmaphorum

OCTOBER 18, 2022

Oculis SA, a global biopharmaceutical company that develops treatments for saving sight and improving eye care with breakthrough innovations, is to combine with the European Biotech Acquisition Corp (EBAC), a special purpose acquisition company (SPAC) that has screened over 100 European biotechnology companies.

Biopharma 59

Biopharma Management Specialization Physicians 59

pharmaphorum

SEPTEMBER 14, 2022

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD). Testing in dry AMD will follow later on, if data from the lead indication is positive.

Safety 52

Safety Leads Patients FDA 52

Pharmaceutical Technology

OCTOBER 18, 2022

Oculis works on developing product candidates for areas with substantial medical needs, including diabetic macular oedema (DME), dry eye disease (DED) and glaucoma. The portfolio of the company comprises three clinical-stage product candidates, namely OCS-01, OCS-02 and OCS-05.

Specialization 59

Specialization Management Medical Pharmaceutical 59

pharmaphorum

NOVEMBER 16, 2022

Wykoff about the results from Apellis Pharmaceuticals’ OAKS study on intravitreal pegcetacoplan for geographic atrophy (GA), otherwise known as atrophic or dry age-related macular degeneration (AMD), a leading cause of blindness worldwide. As the name suggests, AMD is an age-related disease; it becomes more prevalent as we get older.

Safety 95

Safety Patients Consulting Prospecting 95

pharmaphorum

JANUARY 19, 2023

Representing a significant milestone for Vaxxas, it builds on its pre-clinical portfolio into mRNA vaccines, with the potential to expand the company’s vaccine technology pipeline across a number of diseases, including COVID-19.

Transportation 98

Transportation Government Manufacturing 98

MedCity News

MAY 19, 2023

Bausch + Lomb drug Miebo is now FDA approved as a new treatment for dry eye disease. Unlike many products that rewet the eye, Miebo is designed to address one of the factors that leads to dry eyes.

FDA 116

FDA Leads Biopharma Pharma 116

Evolve Your Success

MAY 9, 2023

Clinically, I tend to fall on the side of clinical roles where I try to get more surgeon buy-in and end-user buy-in, but we always deal with hospital administration. I go after the clinical value and I have somewhat found myself in more male-dominated roles. .” You are only dealing with the eye. It can vary.

Medical 52

Medical Sales Medical sales Retail 52

Medgadget

AUGUST 10, 2022

At present, diagnosing sleep disorders is an arduous and expensive business, requiring patients to attend a specialized sleep clinic and wear bulky and uncomfortable equipment, all while attempting to sleep in a strange environment. Ziv Peremen : Sleep monitoring traditionally takes place in dedicated sleep clinics.

Patients 104

Patients Specialization Management Medical 104